Search Results - "Galieni, P."

Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma by Bringhen, S, D'Agostino, M, De Paoli, L, Montefusco, V, Liberati, A M, Galieni, P, Grammatico, S, Muccio, V E, Esma, F, De Angelis, C, Musto, P, Ballanti, S, Offidani, M, Petrucci, M T, Gaidano, G, Corradini, P, Palumbo, A, Sonneveld, P, Boccadoro, M

“…This multicentre, open-label phase 1/2 trial determined safety and efficacy of weekly carfilzomib plus cyclophosphamide–dexamethasone (wKCyd) in newly…”
Get full text

Modified BEAM as conditioning regimen for lymphoma patients undergoing autologous hematopoietic stem cell transplantation by Galieni, P, Troiani, E, Bigazzi, C, Mazzotta, S, Ruggieri, M, Pezzoni, V, Dalsass, A, Mestichelli, F, Caraffa, P, Travaglini, F, Ferretti, S, Angelini, M, Angelini, S, Falcioni, S

Get full text

Primary plasma cell leukemia: a retrospective multicenter study of 73 patients by Pagano, L., Valentini, C.G., De Stefano, V., Venditti, A., Visani, G., Petrucci, M.T., Candoni, A., Specchia, G., Visco, C., Pogliani, E.M., Ferrara, F., Galieni, P., Gozzetti, A., Fianchi, L., De Muro, M., Leone, G., Musto, P., Pulsoni, A.

“…Epidemiological and clinical information on primary plasma cell leukemia (pPCL) are rarely reported. The aims are to evaluate the clinical features, prognostic…”
Get full text

P50 OVERALL SURVIVAL ADVANTAGE OF MONOCLONAL ANTIBODIES BASED‐TREATMENTS IN MULTIPLE MYELOMA PATIENTS RELAPSED AFTER ALLOGENEIC STEM CELL TRANSPLANTATION by Nozzoli, C., Pucillo, M., Martino, M., Giaccone, L., Rambaldi, A., Benedetti, E., Russo, D., Mordini, N., Bernasconi, P., Mangiacavalli, S., Pioltelli, P., Carluccio, P., Galieni, P., Ladetto, M., Sica, S., Isola, M., De Martino, M., Oldani, E., Degrandi, E., Biasco, A., Fanin, R., Saccardi, R., Ciceri, F., Patriarca, F.

Get full text

BU melphalan and auto-SCT in AML patients in first CR: a 'Gruppo Italiano Trapianto di Midollo Osseo (GITMO)' retrospective study by Lemoli, R M, D'Addio, A, Marotta, G, Pezzullo, L, Zuffa, E, Montanari, M, De Vivo, A, Bonini, A, Galieni, P, Carella, A M, Guidi, S, Michieli, M, Olivieri, A, Bosi, A

“…AML patients (total 129; median age =50 years; range 16–72) in first CR received BU and melphalan (BU/Mel) as conditioning regimen before auto-SCT. In all, 82…”
Get full text

Weekly Carfilzomib in combination with cyclophosphamide and dexamethasone (wCCyd) in patients (pts) with newly diagnosed Multiple Myeloma (NDMM): a phase 1/2 study of the European Myeloma Network Trialist Group by Bringhen, S, Gay, F, Rossi, D, Larocca, A, Gentilini, F, Galieni, P, Malfitano, A, Omedé, P, Offidani, M, Liberati, A.M, Gaidano, G, Boccadoro, M, Sonneveld, P, Corradini, P, Palumbo, A

Get full text

Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis by Oggioni, M R, Pozzi, G, Valensin, P E, Galieni, P, Bigazzi, C

“…Bacillus subtilis is a gram-positive, aerobic, spore-forming soil bacterium ubiquitous in the environment. The beneficial effects of B. subtilis spores on the…”
Get full text

Solitary plasmacytoma of bone and extramedullary plasmacytoma: two different entities? by Galieni, P, Cavo, M, Avvisati, G, Pulsoni, A, Falbo, R, Bonelli, M A, Russo, D, Petrucci, M T, Bucalossi, A, Tura, S

“…The objective of this study was to evaluate the similarities between solitary plasmacytoma of bone (SPB) and extramedullary plasmacytoma (EP). The clinical…”
Get more information

Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma by Zinzani, P L, Lauria, F, Rondelli, D, Benfenati, D, Raspadori, D, Bocchia, M, Bendandi, M, Gozzetti, A, Zaja, F, Fanin, R

“…Fludarabine (FLU) is a new antimetabolite chemotherapeutic agent with a promising therapeutic activity in the lymphoproliferative disorders. We performed a…”
Get more information

Salvage Transplant Versus CAR-T Cell Therapy for Relapsed Multiple Myeloma by Gagelmann, Nico, Garderet, Laurent, Iacobelli, Simona, Koster, Linda, Carotti, Alessandra, Schönland, Stefan, Galieni, Piero, Daskalakis, Michael, Roeloffzen, Wilfried, Hunter, Hannah, Duchosal, Michel A., Lenhoff, Stig, Arat, Mutlu, Wulf, Gerald G., Bolam, Simon, Pastore, Domenico, Gedde-Dahl, Tobias, Richardson, Deborah Susan, Mielke, Stephan, Raj, Kavita, Drozd-Sokolowska, Joanna, Hayden, Patrick John, McLornan, Donal P

“…Background: Ide-cel and cilta-cel received regulatory approval for the treatment of patients with relapsed or refractory multiple myeloma (MM) after ≥4 prior…”
Get full text

Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma by Stasi, R, Zinzani, P L, Galieni, P, Lauta, V M, Damasio, E, Dispensa, E, Dammacco, F, Papa, G, Tura, S

“…We investigated the prognostic significance of interleukin-10 (IL-10) and soluble interleukin-2 receptor (sIL-2r) levels in the pretreatment serum of 105…”
Get more information

Variant t(1;15;17)(q23;q22;q23) in a case of acute promyelocytic leukemia by Galieni, P, Marotta, G, Vessichelli, F, Diverio, D, Minoletti, F, Bucalossi, A, Lo Coco, F, Lauria, F

Get more information

Behaviour of human lymphocytic isoenzymes of 5′-nucleotidase by Rosi, F, Agostinho, A.B., Carlucci, F, Zanoni, L, Porcelli, B, Marinello, E, Galieni, P, Tabucchi, A

“…The behaviour of 5′-nucleotidase isoenzymes (ecto-5′-nucleotidase, e-Ns and c-N-II soluble 5′-nucleotidases) was studied in lymphocytes from patients with…”
Get full text

Isoenzymes of 5'-nucleotidase in human lymphocytes by Marinello, E, Tabucchi, A, Carlucci, F, Galieni, P, Rosi, F

Get more information

All-trans retinoic acid (ATRA) in patients with chronic myeloid leukemia in the chronic phase by Russo, D, Regazzi, M, Sacchi, S, Visani, G, Lazzarino, M, Avvisati, G, Pelicci, P G, Dastoli, G, Grandi, C, Iacona, I, Candoni, A, Grattoni, R, Galieni, P, Rupoli, S, Liberati, A M, Maiolo, A T

“…Since in vitro observations indicated that all-trans retinoic acid (ATRA), especially in combination with IFNalpha, can exert significant suppressive effects…”
Get full text

Evaluation of Circulating Endothelial Cells (CECs) as direct marker of endothelial damage in allo-transplanted patients at high risk of hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) by Farina, M, Scaini, M C, Facchinetti, A, Leoni, A, Bernardi, S, Catoni, C, Morello, E, Radici, V, Frioni, Filippo, Campodonico, E, Traverso, G, Cavallaro, G, Olivieri, A, Galieni, P, Renzo, N Di, Patriarca, F, Carluccio, P, Skert, C, Maffini, E, Pellizzeri, S, Campisi, G, Re, F, Benedetti, E, Rosato, A, Almici, C, Chiusolo, P, Peccatori, J, Malagola, M, Poggiana, C, Russo, D

“…Sinusoidal obstruction syndrome (SOS), also known as veno-occlusive disease (VOD), is a rare but potentially fatal complication following allogenic…”
Get full text

2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders by Rondelli, D., Lauria, F., Zinzani, P. L., Raspadori, D., Ventura, M. A., Galieni, P., Birtolo, S., Forconi, F., Algeri, R., Tura, S.

“…:  2‐Chlorodeoxyadenosine (2‐CdA) is a purine analog with cytotoxic activity on both resting and cycling lymphocytes which has been used as salvage therapy in…”
Get full text

Prognostic variables and clinical staging in multiple myeloma by Cavo, M, Galieni, P, Zuffa, E, Baccarani, M, Gobbi, M, Tura, S

“…To evaluate the most important factors in the prognosis and staging of multiple myeloma (MM), the presenting clinical features of 163 previously untreated…”
Get full text

A Novel High Dose Chemotherapy Strategy With Bendamustine in Adjunct to Etoposide, Cytarabine and Melphalan (BeEAM) Followed by Autologous Stem Cell Rescue Is Safe and Highly Effective for the Treatment of Resistant/Relapsed Lymphoma Patients: A Phase I-II Study on 44 Patients by Visani, G, Malerba, L, Stefani, P.M, Capria, S, Galieni, P, Gaudio, F, Specchia, G, Meloni, G, Gherlinzoni, F, Giardini, C, Falcioni, S, Loscocco, F, Cuberli, F, Gobbi, M, Sarina, B, Santoro, A, Rocchi, M, Ocio, E.M, Caballero, D.M, Isidori, A

Get full text

Prognostic Variables and Clinical Staging in Multiple Myeloma by Cavo, Michele, Galieni, Piero, Zuffa, Eliana, Baccarani, Michele, Gobbi, Marco, Tura, Sante

“…To evaluate the most important factors in the prognosis and staging of multiple myeloma (MM), the presenting clinical features of 163 previously untreated…”
Get full text